Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 3Inflammatory Bowel Diseases 2Crohn Disease 2Colitis, Ulcerative 2Lymphoma 1Inflammation 1Hypertension 1Depressive Disorder, Treatment-Resistant 1Depressive Disorder, Major 1Depression 1Bipolar Disorder 1Autoimmune Diseases 1Arthritis, Psoriatic 1

Interventions

Omeprazole 2soybean oil, phospholipid emulsion 1dolutegravir 1Vitamin D 1Tumor Necrosis Factors 1Trimethoprim, Sulfamethoxazole Drug Combination 1Sufentanil 1Sodium Chloride 1Ritonavir 1Riluzole 1Oxycodone 1Nutrition Assessment 1Nucleosides 1Naproxen 1Infliximab 1Fish Oils 1Febuxostat 1Exercise 1Diet 1Dexlansoprazole 1Darunavir 1Colchicine 1Clindamycin 1ClinOleic 1Cephalexin 1Anti-Bacterial Agents 1Allopurinol 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Inflammation × Infliximab × Clear all
NCT02743390 2017-11-09

Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension

University of Campinas, Brazil

Phase 4 Completed
10 enrolled

Hypertension, Inflammation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡